騰盛博藥-B(2137.HK)創上市新高 新冠“特效藥”再獲進展
格隆匯9月13日丨騰盛博藥-B(2137.HK)今日盤中持續拉昇,一度漲超11%至46.95港元,創上市新高價,市值338億港元。騰盛博藥8月25日發佈公吿,稱該公司的新冠中和抗體BRII-196/BRII-198聯合療法在837例疾病進展高風險的患者中,與安慰劑相比,住院及死亡的複合終點降低78%,具有統計學顯著性。這意味着,這款新冠藥物或可以使得住院患者的死亡率降78%。目前這款新冠中和抗體藥物正在國際開展三期臨牀試驗。9月8日,騰盛博藥相關負責人表示,公司的新冠中和抗體新藥的國際三期臨牀研究取得積極結果,藥物距離獲批僅一步之遙,預計今年年底或可獲批使用。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.